Glenmark expecting USFDA nod for 4-6 products this fiscal

Company's capex for this year is Rs 600 crore and majority of this will go for the plant in the US

Glenmark Pharmaceuticals is expecting approvals for four to six new products during the fiscal from the US Food and Drug Administration (USFDA), a senior official said today.

"We are expecting approvals for 4-6 products from the USFDA during this year," Glenmark Pharmaceuticals President and Head-India Business Sujesh Vasudevan told reporters here on the sidelines of launch of Teneligliptin in Telangana.

The company had already got approvals for eight products this year, he added.

Teneligliptin, a new third generation oral anti-diabetic agent, is used for the management of Type 2 Diabetes Mellitus.

Glenmark has launched this molecule under two brands, Ziten and Zita Plus, at Rs 19.90 per tablet.

"... The launch of these two products will lower the daily cost of treatment for a diabetes patient on Gliptin therapy by approximately 55 per cent," Vasudevan said.

Glenmark's diabetes segment is valued at around Rs 100 crore, Vasudevan said, adding it is growing at 20 per cent per annum.

Reacting to a query, he said, "The capex for this year is Rs 600 crore and majority of this will go for the plant in the US.